The tweet was deleted by the author.
But we saved everything 🙂.
Tyra Biosciences announced the initial Phase 2 results from its SURF302 clinical study, which evaluates dabogratinib for the treatment of bladder cancer.
The company noted that the September 9 update on the ongoing development attracted media attention, with multiple outlets covering the new data and its implications for dabogratinib as a therapeutic option.
View post on X Loading...
Earlier this year, Tyra Biosciences presented research breakthroughs in IR NMIBC bladder cancer care at the IBCG26 Annual Retreat. The company engaged with industry peers during the IBC26 forum, highlighting its clinical focus. Tyra's continued updates reflect ongoing developments in its bladder cancer pipeline.